{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:42:54Z","timestamp":1771656174946,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["psy-journal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.psychres.2015.09.030","type":"journal-article","created":{"date-parts":[[2015,9,21]],"date-time":"2015-09-21T22:05:53Z","timestamp":1442873153000},"page":"419-423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Associations between five-factor model of the Positive and Negative Syndrome Scale and plasma levels of monoamine metabolite in patients with schizophrenia"],"prefix":"10.1016","volume":"230","author":[{"given":"Kenya","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Kanno-Nozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Horikoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirobumi","family":"Mashiko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-Ichi","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirooki","family":"Yabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2015.09.030_bib1","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0278-5846(02)00218-X","volume":"26","author":"Aymard","year":"2002","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2015.09.030_bib2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0447.1990.tb06442.x","article-title":"Plasma 3-methoxy-4-hydroxyphenylglycol in manic patients: relationships with clinical variables","volume":"81","author":"Azorin","year":"1990","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.psychres.2015.09.030_bib3","first-page":"248","article-title":"Plasma catecholamine metabolites and early response to haloperidol","volume":"45","author":"Bowers","year":"1984","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2015.09.030_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.psychres.2010.11.003","article-title":"Abnormal plasma monoamine metabolism in schizophrenia and its correlation with clinical responses to risperidone treatment","volume":"188","author":"Cai","year":"2011","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2015.09.030_bib5","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/0006-3223(90)90442-5","article-title":"Plasma catecholamine metabolites in schizophrenics: evidence for the two-subtype concept","volume":"27","author":"Chang","year":"1990","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2015.09.030_bib6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000117988","article-title":"Plasma noradrenaline and clinical psychopathology in schizophrenia. A correlation analysis","volume":"10","author":"Dajas","year":"1983","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.psychres.2015.09.030_bib7","first-page":"347","article-title":"Effects of clozapine and typical antipsychotic drugs on plasma 5-HT turnover and impulsivity in patients with schizophrenia: a cross-sectional study","volume":"25","author":"Dursun","year":"2000","journal-title":"J. Psychiatry\u00a0Neurosci."},{"key":"10.1016\/j.psychres.2015.09.030_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0920-9964(02)00302-X","article-title":"The factor structure for the Positive and Negative Syndrome Scale(PANSS) in recent-onset psychosis","volume":"61","author":"Emsley","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2015.09.030_bib9","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1021\/ac00126a067","article-title":"Simultaneous determination of free homovanillicacid, (3-methoxy-4-hydroxyphenyl)ethyleneglycol, and vanilmandelic acid in human plasma by high-performance liquid chromato-graphy coupled with dual-electrode coulometric electrochemical detection","volume":"58","author":"Gerhardt","year":"1986","journal-title":"Anal. Chem."},{"key":"10.1016\/j.psychres.2015.09.030_bib10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0920-9964(93)90074-S","article-title":"Haloperidol response and plasma catecholamines and their metabolites","volume":"10","author":"Green","year":"1993","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2015.09.030_bib11","first-page":"21","article-title":"Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients","volume":"22","author":"Hori","year":"2007","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2015.09.030_bib12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000118821","article-title":"Plasma free 3-methoxy-4-hydroxyphenylglycol in acute schizophrenics before and after treatment","volume":"25","author":"Kaneko","year":"1992","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.psychres.2015.09.030_bib13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2015.09.030_bib14","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/schbul\/16.3.537","article-title":"Pyramidical model of schizophrenia","volume":"16","author":"Kay","year":"1990","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2015.09.030_bib15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.psychres.2011.10.006","article-title":"Evaluation of the factor structure of symptoms in patients with schizophrenia","volume":"197","author":"Kim","year":"2012","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2015.09.030_bib16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0920-9964(99)00171-1","article-title":"Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics","volume":"44","author":"Kim","year":"2000","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2015.09.030_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1126\/science.6849119","article-title":"Relation between plasma and cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylglycol","volume":"219","author":"Kopin","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.psychres.2015.09.030_bib18","doi-asserted-by":"crossref","first-page":"e100634","DOI":"10.1371\/journal.pone.0100634","article-title":"The noradrenaline metabolite MHPG is a candidate biomarker from the manic to the remission state in bipolar disorder I: a clinical naturalistic study","volume":"9","author":"Kurita","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.psychres.2015.09.030_bib19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1126\/science.7350667","article-title":"Schizophrenia: elevated cerebrospinal fluid norepinephrine","volume":"207","author":"Lake","year":"1980","journal-title":"Science"},{"key":"10.1016\/j.psychres.2015.09.030_bib20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3371\/CSRP.3.2.5","article-title":"The five-factor structure of the PANSS: a critical review of its consistency across studies","volume":"3","author":"Lehoux","year":"2009","journal-title":"Clin. Schizophr. Relat. Psychos."},{"key":"10.1016\/j.psychres.2015.09.030_bib21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00005053-199411000-00006","article-title":"Five-factor model of schizophrenia. Initial validation","volume":"182","author":"Lindenmayer","year":"1994","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.psychres.2015.09.030_bib22","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/j.1471-4159.1980.tb11240.x","article-title":"Estimates of dopamine and serotonin synthesis by the awake human brain","volume":"34","author":"Maas","year":"1980","journal-title":"J. Neurochem."},{"key":"10.1016\/j.psychres.2015.09.030_bib23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/npp.1993.11","article-title":"Studies of catecholamine metabolism in schizophrenia\/psychosis-I","volume":"8","author":"Maas","year":"1993","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2015.09.030_bib24","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0006-3223(92)90110-L","article-title":"Biogenic amine metabolites in plasma of drug-naive schizophrenic patients: associations with symptomatology","volume":"32","author":"Markianos","year":"1992","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2015.09.030_bib25","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/0006-3223(91)90309-A","article-title":"Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis","volume":"30","author":"Mazure","year":"1991","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2015.09.030_bib26","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/JCP.0b013e31823f87ac","article-title":"Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia","volume":"32","author":"Miura","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2015.09.030_bib27","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0006-3223(96)00244-2","article-title":"First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment","volume":"41","author":"Nagaoka","year":"1997","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2015.09.030_bib28","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/JCP.0b013e3181f2288e","article-title":"Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF","volume":"30","author":"Nikisch","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2015.09.030_bib29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hup.368","article-title":"Relations of clinical features, subgroups and medication to serum monoamines in schizophrenia","volume":"17","author":"Oades","year":"2002","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.psychres.2015.09.030_bib30","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/archpsyc.1990.01810190041006","article-title":"Cerebrospinal fluid and plasma monoamine metabolites and their relation topsychosis: implications for regional brain dysfunction in schizophrenia","volume":"47","author":"Pickar","year":"1990","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.psychres.2015.09.030_bib31","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0006-3223(97)00451-4","article-title":"Pretreatment plasma homovanillic acid in schizophrenia and schizoaffective disorder: the influence of demographic variables and the inpatient drug-free period","volume":"44","author":"Sharma","year":"1998","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2015.09.030_bib32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/01.jcp.0000104904.75206.19","article-title":"Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment","volume":"24","author":"Shinkai","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2015.09.030_bib33","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.psychres.2014.08.031","article-title":"Impacts of age on plasma monoamine metabolite concentrations in a large cohort of healthy individuals","volume":"220","author":"Soda","year":"2014","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2015.09.030_bib34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000071826","article-title":"Higher plasma 5-hydroxyindole acetic acid levels are associated with SSRI-induced nausea","volume":"48","author":"Ueda","year":"2003","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.psychres.2015.09.030_bib35","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1177\/0269881109106899","article-title":"Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism","volume":"24","author":"Umene-Nakano","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2015.09.030_bib36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.schres.2005.09.002","article-title":"Factor structure and external validity of the PANSS revisited","volume":"82","author":"Van den Oord","year":"2006","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2015.09.030_bib37","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.schres.2014.08.015","article-title":"Antidepressants for cognitive impairment in schizophrenia \u2013 a systematic review and meta-analysis","volume":"159","author":"Vernon","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2015.09.030_bib38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000285058","article-title":"Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale.\u00a0The PANSS Study Group","volume":"30","author":"White","year":"1997","journal-title":"Psychopathology"},{"key":"10.1016\/j.psychres.2015.09.030_bib39","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/hup.804","article-title":"Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders","volume":"21","author":"Yoshimura","year":"2006","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.psychres.2015.09.030_bib40","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3109\/15622970802309617","article-title":"Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients","volume":"11","author":"Yoshimura","year":"2010","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2015.09.030_bib41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0022-3956(01)00008-5","article-title":"Plasma homovanillic acid in untreated schizophrenia \u2013 relationship with symptomatology and sex","volume":"35","author":"Zhang","year":"2001","journal-title":"J. Psychiatr. Res."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016517811530370X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016517811530370X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T08:00:37Z","timestamp":1537344037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016517811530370X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S016517811530370X"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2015.09.030","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Associations between five-factor model of the Positive and Negative Syndrome Scale and plasma levels of monoamine metabolite in patients with schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2015.09.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}